Crouse Health Online: Wellness is just a click away.
Share Share
  |  Connect with Us: 
large
med
small
Text Size
 

Health News



Staying on Gleevec Seems to Help Gastro Cancer Patients

Staying on Gleevec Seems to Help Gastro Cancer Patients

09/22/10

TUESDAY, Sept. 21 (HealthDay News) -- Continuous treatment with imatinib (Gleevec) is recommended for patients with advanced gastrointestinal cancer, a new study suggests.

The study included 50 patients with advanced gastrointestinal stromal tumors (GIST) who'd been receiving Gleevec for three years and had no disease progression. The patients were randomly selected to either continue or stop treatment.

The patients were assessed every three months with CT scans. The median time to disease progression was nine months among patients whose treatment was interrupted and was not reached in the group who continued treatment, the investigators found.

In addition, after nearly three years of follow-up, the researchers noted that two-year survival without disease progression was 80 percent among those who continued treatment but only 16 percent among those whose treatment had been interrupted, according to the report published in the Sept. 22 online edition of The Lancet Oncology.

The findings show that three years of treatment with Gleevec does not totally eliminate cancer-causing cells, which means the disease can recur when treatment is stopped, Dr. Axel Le Cesne, of the Institute Gustave Roussy in Villejuif, France, and colleagues explained in a news release from the journal's publisher.

"There was further tumor control in all cases after the reintroduction of [Gleevec], and the time to secondary resistance to [Gleevec] was similar in the two groups, which shows that [Gleevec] interruption neither prevents nor promotes the emergence of [Gleevec] resistance in GIST cells," Le Cesne and colleagues wrote in the report.

The authors concluded that because three years of treatment with Gleevec does not eliminate the remaining dormant cancer cells and cure patients with GIST that has spread, it is not recommended that Gleevec is discontinued unless the patient experiences significant toxic effects.

Funding for the study was provided by Conticanet, the Ligue Contre Le Cancer du Rhone and Novartis, maker of Gleevec.

More information

The American Cancer Society has more about gastrointestinal stromal tumors.

Copyright © 2010 HealthDay. All rights reserved.

Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.

OF INTEREST:
 

Latest News

Crouse Hospital Appoints Chief Information Officer
more >

MedEx Bedside Prescription Delivery Service

Free service offers convenience, patient education at discharge.
more >

CrouseSports Express After-Hours Ortho Care

Immediate care of orthopedic injuries in kids and adults.
more >

Weight Loss Surgery

Is it right for you? Attend a free information seminar held twice monthly.
more >

Quality at Crouse

See how Crouse Hospital strives to provide the best in patient care.
more >

Cheer Up That Special Someone

Say get well or welcome a new arrival with a gift purchased right at Crouse.

more >

Make an Online Donation Now

Your donation of any amount helps support Crouse services & programs in a meaningful way.
more >

Shop Online Now

Say get well, thinking of you or welcome new baby with a unique gift from the Crouse Gift Shop.

more >